Gastrointestinal Stromal Tumors

Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Gastrointestinal Stromal Tumors Information Center has current, evidence-based information for you. Get the facts about gastrointestinal stromal tumors early detection, treatment, and survivorship, and stay up to date with ongoing gastrointestinal stromal tumors research that could impact your treatment decisions through our daily cancer news.

CancerConnect Gastrointestinal Stromal Tumors Community & Discussions

You are not alone—The CancerConnect Gastrointestinal Stromal Tumors Community is the leading Social Media Application for Gastrointestinal Stromal Tumors patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.

GASTROINTESTINAL STROMAL TUMORS NEWS TIPS & FEATURES

New Drug Shows Improved Outcomes for Patients with Advanced Metastatic Mid-gut Neuroendocrine Tumors

January 23rd, 2017

New Drug Shows Improved Outcomes for Patients with Advanced Metastatic Mid-gut Neuroendocrine Tumors

A new therapy in development for the treatment of mid-gut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, […]


Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents

February 11th, 2016

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or […]


Stivarga Approved for Advanced Gastrointestinal Stromal Tumors

March 12th, 2013

Stivarga Approved for Advanced Gastrointestinal Stromal Tumors

The U.S. Food and Drug Administration (FDA) expanded the approved use of Stivarga® (regorafenib)to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be […]


Cancer Navigators Help Patients with Gastrointestional Stromal Tumors

March 17th, 2012

Cancer Navigators Help Patients with Gastrointestional Stromal Tumors

Cancer navigators offer patients with gastrointestional stromal tumors guidance as they find their way through a cancer journey. By Sally Abrahms In 1992 Anne McNerney […]


Anemia: A Manageable Side Effect Gastrointestinal Stromal Tumors

October 25th, 2011

Anemia: A Manageable Side Effect Gastrointestinal Stromal Tumors

Anemia, one of the most common side effects associated with cancer, affects over 60 percent of cancer patients. Anemia may occur as either a direct […]


Clinical Trial Participation Is Inadequate

August 31st, 2011

Clinical Trial Participation Is Inadequate

A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, […]


Preparing for Surgery

June 22nd, 2011

Preparing for Surgery

You can help ensure that your surgery and recovery go smoothly and that you have the best outcome possible by preparing yourself ahead of time. […]


Three Years of Treatment with Gleevec Improves Survival in Gastrointestinal Stromal Tumors (GIST)

June 9th, 2011

Three Years of Treatment with Gleevec Improves Survival in Gastrointestinal Stromal Tumors (GIST)

Treatment with Gleevec® (imatinib) for 3 years following surgery significantly improves survival compared with the standard one-year therapy for patients with gastrointestinal stromal tumors (GIST). […]


Know the Signs of Depression in Cancer Patients

April 7th, 2011

Know the Signs of Depression in Cancer Patients

Because a significant number of cancer patients—an estimated 25 percent—experience major depression at some point during their illness, recognizing the signs of depression among patients […]


Nexavar Shows Promise against Drug-Resistant GIST

February 1st, 2011

Nexavar Shows Promise against Drug-Resistant GIST

Among patients with gastrointestinal stromal tumors (GIST) that were resistant to both Gleevec® (imatinib) and Sutent® (sunitinib), treatment with Nexavar® (sorafenib) resulted in tumor shrinkage […]


More News →